This clinical trial is focused on the treatment of a condition known as incisional hernia. An incisional hernia occurs when tissue pushes through a weak spot in the abdominal wall, often at the site of a previous surgical incision. The study is investigating the use of a treatment called botulinum toxin A, specifically a product named XEOMIN, which is a type of protein that can help relax muscles. The purpose of the study is to see if injecting botulinum toxin A into the muscles of the abdominal wall before surgery can reduce complications after the surgical repair of large incisional hernias.

Participants in the study will receive either the botulinum toxin A injection or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who receives the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations. The trial will follow participants through their surgery and recovery, monitoring for any complications and measuring various outcomes over a period of time, including up to one year after surgery.

The study aims to gather information on the effectiveness of botulinum toxin A in reducing the rate of complications after hernia repair surgery. It will also look at other factors such as the length of hospital stay, the severity of any complications, and the overall recovery process. By comparing the results between those who receive the treatment and those who receive the placebo, researchers hope to determine if botulinum toxin A can improve surgical outcomes for patients with large incisional hernias.